10-K: Theriva Biologics Details Share Structure and Anti-Takeover Measures in 10-K Filing

Theriva Biologics outlines its common stock characteristics, voting rights, and anti-takeover provisions in its latest 10-K filing.

Summary

• Theriva Biologics has 350,000,000 authorized shares of common stock, each with one vote.
• Holders of common stock are entitled to dividends if declared by the board, and share in net assets upon liquidation after debts are paid.
• The company's stock is listed on the NYSE American under the symbol TOVX.
• A registration statement for securities issued to Intrexon was declared effective on April 29, 2013.
• The company's articles of incorporation and bylaws include anti-takeover provisions, such as the lack of cumulative voting rights for directors.
• Nevada law also includes anti-takeover provisions, including business combination and control share acquisition statutes.
• The company's common stock is fully paid and nonassessable.
• The transfer agent and registrar for the common stock is Equiniti Trust Company.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's stock structure and governance. It does not express any strong positive or negative sentiment.

Positives

• The company has a clear structure for its common stock and shareholder rights.
• The company has a transfer agent and registrar for its common stock.
• The company has a registration statement in place for certain securities.

Negatives

• The lack of cumulative voting rights makes it more difficult for stockholders to replace the board of directors.
• Anti-takeover provisions could discourage potential acquisitions, even if beneficial to stockholders.
• The company has authorized but unissued shares that could be used to discourage a takeover.

Risks

• Anti-takeover provisions in the company's charter and Nevada law could discourage potential acquisitions.
• The lack of cumulative voting rights makes it more difficult for stockholders to replace the board of directors.
• The company has authorized but unissued shares that could be used to discourage a takeover.
• The company is subject to Nevada's business combination and control share acquisition statutes, which could delay or prevent mergers or changes in control.

Future Outlook

The company may issue additional shares of common stock for various purposes, including raising capital, funding acquisitions, and employee compensation.

Industry Context

The document provides insight into the company's capital structure and governance, which is typical for public companies. The anti-takeover provisions are common in corporate charters and state laws to protect the company from hostile takeovers.

Comparison to Industry Standards

• The authorized share count is typical for a company of this size and stage.
• The anti-takeover provisions are common in corporate charters and state laws to protect the company from hostile takeovers, similar to companies like Amgen and Gilead.
• The lack of cumulative voting rights is a common practice, but some companies, like those with activist investors, may have cumulative voting rights.
• The use of a transfer agent and registrar is standard practice for publicly traded companies, similar to companies like Pfizer and Moderna.

Stakeholder Impact

• Shareholders may be impacted by the anti-takeover provisions, which could limit their ability to influence the company's direction.
• Shareholders may experience dilution if the company issues additional shares of common stock.
• Potential acquirers may be discouraged by the anti-takeover provisions.

Next Steps

• The company may issue additional shares of common stock for various purposes.
• The company may need to comply with ongoing requirements related to the registration statement.

Key Dates

Keywords

common stock, anti-takeover, voting rights, dividends, liquidation rights, NYSE American, Nevada law, shareholder rights, registration statement